Table 2. Clinical, virological, and histological data of SVR and NR patients to PEG-INF-α2b/RBV therapy.
| Parameter | SVR (n = 69) | NR (n = 37) | P value |
|---|---|---|---|
| Sex | 1 | ||
| Male, n (%) | 52 (75.36%) | 28 (75.67%) | |
| Female, n (%) | 17 (24.36%) | 9 (24.32%) | |
| Age (years) | 43.90 ±9.37 | 44.93±6.85 | 0.7 |
| Range (years) | (22–60) | (30–56) | |
| ALT (IU/l) | 54.87±24.89 | 66.78±25.13 | 0.02* |
| AST (IU/I) | 51.37±18.26 | 63.5±26.8 | 0.007* |
| ALP (IU/l) | 98.7±45.4 | 127.5±56.6 | 0.005* |
| Total bilirubin (mg/dl) | 0.75±0.29 | 0.74±0.27 | 0.619 |
| Direct bilirubin (mg/dl) | 0.43±0.22 | 0.53±0.53 | 0.171 |
| Albumin (g/dl) | 4.05±0.65 | 3.85±0.83 | 0.174 |
| AFP (ng/ml) | 4.12±3.16 | 6.33±4.12 | 0.003* |
| Hemoglobin (g/dl) | 16.27±7.26 | 13.9±1.2 | 0.42 |
| Total leukocyte count (x103/mm3) | 6.53± 2.15 | 6.3 ± 2.05 | 0.596 |
| Platelet count (x103/mm3) | 219.8±62 | 189.6±41.3 | 0.009* |
| Viral load (x 105 IU/ml) | 2 (0.09–7.98) a | 7.51 (1.1–30.75) a | 0.001* |
| Fibrosis stage, n (%) | 0.13 | ||
| F1 | 39 (56.5%) | 14 (38%) | |
| F2 | 20 (29%) | 13 (35%) | |
| F3 | 10 (14.5%) | 10 (27%) | |
| Activity, n (%) | 0.001* | ||
| A1 | 50 (72%) | 16 (43%) | |
| A2 | 12 (17%) | 19 (52.5%) | |
| A3 | 7 (10.5%) | 2 (4.5%) |
Data are expressed by number (percentage), mean ± SD, or median (25%-75% percentiles) for viral load.
a Data were analyzed by Mann Whitney U-test.
* indicates statistical significance (P<0.05).